Back to results

Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever

Primary Purpose

Dengue Fever

Status

Completed

Phase

Phase 1

Locations

Colombia

Study Type

Interventional

Intervention

TDV - Low Dose

TDV - High Dose

Placebo

About this trial

This is an interventional prevention trial for Dengue Fever focused on measuring dengue fever, live attenuated tetravalent dengue vaccine, TDV, Drug therapy

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Is male or female aged 18 to 45 years, inclusive, at time of screening.
Is in good health as determined by medical history, physical examination, and clinical safety laboratory examinations.
Has body mass index (BMI) in the range 18-27 kilogram per square meter (kg/m^2).
Has negative serology for Human Immunodeficiency Virus (HIV), Hepatitis C antibody, and Hepatitis B surface antigen.
Females of child bearing potential must have a negative urine pregnancy test result during screening and a negative urine pregnancy test immediately prior to vaccination and be willing to use oral, implantable, transdermal or injectable contraceptives or another reliable means of contraception approved by the Investigator (intrauterine device, female condom, diaphragm with spermicidal, cervical cap, use of condom by the sexual partner or a sterile sexual partner, or abstinence) from screening until after the last blood sample (at Day 270).
Is willing and able to give written informed consent to participate.
Is willing and able to communicate with the Investigator and understand the requirements of the study.

Exclusion Criteria:

Has any condition which would limit the participant's ability to complete the study.
Clinically significant hematological, renal, hepatic, pulmonary, central nervous system, cardiovascular or gastrointestinal disorders.
Has abnormal electrocardiogram (ECG).
Has febrile illness (temperature greater than or equal to (>=) 38 degree Celsius (°C) or 100.4 degree Fahrenheit (°F) or moderate or severe acute illness or infection within three days of vaccination.
Diabetes mellitus.
Has allergy to penicillin, neomycin, streptomycin or gentamicin.
Hypersensitivity to any vaccine.
Seropositivity to any of the four dengue serotypes (TDV-1, TDV-2, TDV-3 or TDV-4), yellow fever (YF) virus or West Nile (WN) virus.
Has previous vaccination (in a clinical trial or with an approved product) against flaviviruses including dengue, YF or WN.
Has planned vaccination against YF throughout the duration of this study.
Has receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
Planned receipt of any vaccine in the 4 weeks following each of the vaccinations in this study.
Travel to dengue-endemic areas in the two months prior to study start or planned travel to dengue-endemic areas during the study period, including low altitude regions of Colombia where dengue is endemic.
Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months prior to the first vaccination, or long- term (at least 2 weeks within the previous 3 months) systemic corticosteroids therapy (at a dose of at least 0.5 milligram per kilogram per day [mg/kg/day]) prior to the first vaccination.
Has a history of recurring migraines or on prescription medication for treatment of recurring headaches or migraines.
Use of any non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen or antihistamines for the 3 days immediately prior to each vaccination.
Use of prescription or over the counter medications 7 days before the first vaccination (Day 0), excluding contraceptives and painkillers containing NSAIDs or acetaminophen, cold remedies, hormone replacement and antihistamines.
Positive urine screen for cocaine, amphetamines, opiates, or cannabinoids.
Receipt of any other investigational product or participation in any other clinical trial in the month before the first vaccination (Day 0) or during the conduct of this study.
Receipt of blood products or immunoglobulins 8 weeks before the first vaccination (Day 0) or planned use during the study period.
Donation of blood 6 weeks before the first vaccination (Day 0) or at any time during the study.
Females who are pregnant or lactating.

Sites / Locations

Program For The Study and Control of Tropical Diseases

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Placebo Comparator

Arm Label

Group 1: Low Dose; SC

Group 2: Low Dose; ID

Group 3: High Dose; SC

Group 4: High Dose; ID

Placebo (SC)

Placebo (ID)

Arm Description

TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.

TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.

TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.

TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.

Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.

Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.

Outcomes

Primary Outcome Measures

Number of Participants With Local Injection Site Reaction by Severity

Solicited local reactions were reported using a participant diary. Pain was categorized as Mild (aware of pain but it does not interfere with daily activity and no pain medication is taken); Moderate (aware of pain; there is interference with daily activity or it requires use of pain medication); Severe (aware of pain and it prevents daily activity), redness was categorized as Mild (greater than [>] 15 millimeter [mm]); Moderate as (15-30 mm); Severe (>30 mm), swelling was categorized as Mild (<15 mm); Moderate (15-30 mm); Severe (>30 mm), and itching was categorized as Mild (slight itching at injection site); Moderate (moderate itching at injection extremity); Severe (itching over entire body).

Number of Participants With Systemic Adverse Events (AEs) by Severity

Solicited systemic AEs were reported using a participant diary. Solicited systemic AEs included fever (>= 37.8°C), headache, muscle pain, joint pain, eye pain, photophobia, fatigue, body rash, nausea, vomiting and other (any other symptom not listed in the diary) and were categorized as Mild: transient symptoms, discomfort noticed but easily tolerated, no interference to normal daily activities; Moderate: marked symptoms, moderate interference with daily activities; Severe: considerable interference with daily activities.

Number of Participants With Solicited Local and Systemic AEs

Number of Participants With Unsolicited Local and Systemic AEs

Secondary Outcome Measures

Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes After First Vaccination

GMT was assessed for the four dengue serotypes: Dengue TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95 percent (%) confidence interval (CIs) were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.

GMTs of All Four Dengue Serotypes After Second Vaccination

GMT was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95% CIs were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.

Rate of Seroconversion to Each of Four Dengue Serotypes After the First Vaccination

Seroconversion was defined as a Plaque Reduction Neutralization Test (PRNT) titer resulting in 50% reduction in plaques (PRNT[50]) >=10 (if the pre-vaccination PRNT[50] value was <10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was >=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was >=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit.

Rate of Seroconversion to Each of Four Dengue Serotypes After the Second Vaccination

Seroconversion was defined as a PRNT titer resulting in 50% reduction in plaques (PRNT[50]) >=10 (if the pre-vaccination PRNT[50] value was <10, indicated as a value of 5 in the immunogenicity data collection sheet) OR a PRNT(50) value that was >=4-fold the pre-vaccination titer value (if the pre-vaccination PRNT[50] value was >=10). Seroconversion was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution. Percentages are based on the number of participants in the FAS with non-missing MN assay samples at each visit (n).

Percentage of Participants With Durability of Immune Response

Immune response was considered durable if the participant had detectable neutralizing antibodies (seroconversion) to all 4 dengue serotypes at 90 and 180 days after the second dose (i.e. Days 180 and 270, respectively). Seroconversion is defined as post-vaccination PRNT(50) titer >=10 where pre-vaccination PRNT 50 titer <10, or post-vaccination PRNT(50) Titer >=4-fold the pre-vaccination PRNT(50) titer value where pre-vaccination PRNT(50) titer >=10. Percentage of participants with seroconversion on Days 180 and 270 are based on the number of participants in the FAS with non-missing MN assay samples at each visit. The 95% CIs for percentages are the exact CIs (%) based upon the binomial distribution.

Number of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strain Serotypes After the First and Second Vaccination

Serotype-specific vaccine viremia was assessed for the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Only those serotypes and time-points where at least 1 participant had serotype-specific vaccine viremia detection were reported.

Duration of Vaccine Viremia

Titers of Vaccine Viremia

Full Information

NCT ID

NCT01224639

First Posted

October 9, 2010

Last Updated

June 17, 2018

Sponsor

Inviragen Inc.

1. Study Identification

Unique Protocol Identification Number

NCT01224639

Brief Title

Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever

Official Title

Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults

Study Type

Interventional

2. Study Status

Record Verification Date

June 2018

Overall Recruitment Status

Completed

Study Start Date

October 11, 2010 (Actual)

Primary Completion Date

June 9, 2011 (Actual)

Study Completion Date

November 9, 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Inviragen Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous (SC) or intradermal (ID) injection at two dose levels (low and high). The vaccine will be given as two doses 90 days apart. Safety assessments include injection site evaluation and adverse events. The immune response generated after vaccination will be assessed up to 9 months after the first vaccination.

Detailed Description

This is a single center, placebo-controlled, randomized study assessing the safety and tolerability of two dose levels (low and high) of TDV administered subcutaneously or intradermally in two doses separated by an interval of 90 days. Initial dosing of low dose cohort will be performed and Day 21 safety assessed prior to administration of second dose to low dose cohort on Day 90 and initial dosing of high dose cohort. Day 21 safety for the high dose cohort will be assessed prior to administration of second dose for this cohort. Safety (local injection site reactions and solicited and unsolicited adverse events) will be assessed through Day 120 post-first (1 month after the second dose). Immunogenicity will be assessed at specified time points up to Day 120 post-prime (1 month after the second dose) and again on Days 180 and 270 (6 and 9 months post-first).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Dengue Fever

Keywords

dengue fever, live attenuated tetravalent dengue vaccine, TDV, Drug therapy

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

96 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Group 1: Low Dose; SC

Arm Type

Experimental

Arm Description

TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.

Arm Title

Group 2: Low Dose; ID

Arm Type

Experimental

Arm Description

TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.

Arm Title

Group 3: High Dose; SC

Arm Type

Experimental

Arm Description

TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.

Arm Title

Group 4: High Dose; ID

Arm Type

Experimental

Arm Description

TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.

Arm Title

Placebo (SC)

Arm Type

Placebo Comparator

Arm Description

Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.

Arm Title

Placebo (ID)

Arm Type

Placebo Comparator

Arm Description

Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.

Intervention Type

Biological

Intervention Name(s)

TDV - Low Dose

Other Intervention Name(s)

Live attenuated tetravalent dengue vaccine

Intervention Description

TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU

Intervention Type

Biological

Intervention Name(s)

TDV - High Dose

Other Intervention Name(s)

Live attenuated tetravalent dengue vaccine

Intervention Description

TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.

Intervention Type

Biological

Intervention Name(s)

Placebo

Other Intervention Name(s)

PBS

Intervention Description

Phosphate Buffered Saline (PBS)

Primary Outcome Measure Information:

Title

Number of Participants With Local Injection Site Reaction by Severity

Description

Time Frame

Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)

Title

Number of Participants With Systemic Adverse Events (AEs) by Severity

Description

Time Frame

Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)

Title

Number of Participants With Solicited Local and Systemic AEs

Time Frame

Within 14 days after either of the vaccination given on Day 1 or 90 (Day 14 for first vaccination, Day 104 for second vaccination)

Title

Number of Participants With Unsolicited Local and Systemic AEs

Time Frame

Baseline up to 30 days after second vaccination (Day 120)

Secondary Outcome Measure Information:

Title

Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes After First Vaccination

Description

Time Frame

Days 14, 30, 60 and 90 after first vaccination

Title

GMTs of All Four Dengue Serotypes After Second Vaccination

Description

GMT was assessed for the four dengue serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. GMTs and 95% CIs were calculated by taking the anti-logs of the means and 95% CI of the log transformed titers.

Time Frame

Days 14 and 30 after second vaccination (Day 104 and 120 respectively)

Title

Rate of Seroconversion to Each of Four Dengue Serotypes After the First Vaccination

Description

Time Frame

Days 14, 30, 60 and 90 after first vaccination

Title

Rate of Seroconversion to Each of Four Dengue Serotypes After the Second Vaccination

Description

Time Frame

Days 14 and 30 after second vaccination (Days 104 and 120 respectively)

Title

Percentage of Participants With Durability of Immune Response

Description

Time Frame

Days 180 and 270

Title

Number of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strain Serotypes After the First and Second Vaccination

Description

Time Frame

Baseline and at multiple time points up to Day 14 after each vaccination

Title

Duration of Vaccine Viremia

Time Frame

14 Days after each vaccination

Title

Titers of Vaccine Viremia

Time Frame

14 Days after each vaccination

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

45 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Is male or female aged 18 to 45 years, inclusive, at time of screening. Is in good health as determined by medical history, physical examination, and clinical safety laboratory examinations. Has body mass index (BMI) in the range 18-27 kilogram per square meter (kg/m^2). Has negative serology for Human Immunodeficiency Virus (HIV), Hepatitis C antibody, and Hepatitis B surface antigen. Females of child bearing potential must have a negative urine pregnancy test result during screening and a negative urine pregnancy test immediately prior to vaccination and be willing to use oral, implantable, transdermal or injectable contraceptives or another reliable means of contraception approved by the Investigator (intrauterine device, female condom, diaphragm with spermicidal, cervical cap, use of condom by the sexual partner or a sterile sexual partner, or abstinence) from screening until after the last blood sample (at Day 270). Is willing and able to give written informed consent to participate. Is willing and able to communicate with the Investigator and understand the requirements of the study. Exclusion Criteria: Has any condition which would limit the participant's ability to complete the study. Clinically significant hematological, renal, hepatic, pulmonary, central nervous system, cardiovascular or gastrointestinal disorders. Has abnormal electrocardiogram (ECG). Has febrile illness (temperature greater than or equal to (>=) 38 degree Celsius (°C) or 100.4 degree Fahrenheit (°F) or moderate or severe acute illness or infection within three days of vaccination. Diabetes mellitus. Has allergy to penicillin, neomycin, streptomycin or gentamicin. Hypersensitivity to any vaccine. Seropositivity to any of the four dengue serotypes (TDV-1, TDV-2, TDV-3 or TDV-4), yellow fever (YF) virus or West Nile (WN) virus. Has previous vaccination (in a clinical trial or with an approved product) against flaviviruses including dengue, YF or WN. Has planned vaccination against YF throughout the duration of this study. Has receipt of any vaccine in the 4 weeks preceding the first trial vaccination. Planned receipt of any vaccine in the 4 weeks following each of the vaccinations in this study. Travel to dengue-endemic areas in the two months prior to study start or planned travel to dengue-endemic areas during the study period, including low altitude regions of Colombia where dengue is endemic. Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months prior to the first vaccination, or long- term (at least 2 weeks within the previous 3 months) systemic corticosteroids therapy (at a dose of at least 0.5 milligram per kilogram per day [mg/kg/day]) prior to the first vaccination. Has a history of recurring migraines or on prescription medication for treatment of recurring headaches or migraines. Use of any non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen or antihistamines for the 3 days immediately prior to each vaccination. Use of prescription or over the counter medications 7 days before the first vaccination (Day 0), excluding contraceptives and painkillers containing NSAIDs or acetaminophen, cold remedies, hormone replacement and antihistamines. Positive urine screen for cocaine, amphetamines, opiates, or cannabinoids. Receipt of any other investigational product or participation in any other clinical trial in the month before the first vaccination (Day 0) or during the conduct of this study. Receipt of blood products or immunoglobulins 8 weeks before the first vaccination (Day 0) or planned use during the study period. Donation of blood 6 weeks before the first vaccination (Day 0) or at any time during the study. Females who are pregnant or lactating.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Ivan D Velez, MD, Ph.D.

Organizational Affiliation

PECET, Universidad the Antioquia, Medellin, Colombia

Official's Role

Principal Investigator

Facility Information:

Facility Name

Program For The Study and Control of Tropical Diseases

City

Medellin

Country

Colombia

12. IPD Sharing Statement

Citations:

PubMed Identifier

25087476

Citation

Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL, Luy BE, Arguello J, Beatty ME, Santangelo J, Gordon GS, Huang CY, Stinchcomb DT. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014 Sep;14(9):830-8. doi: 10.1016/S1473-3099(14)70811-4. Epub 2014 Jul 23.

Results Reference

derived

Learn more about this trial

Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever

We'll reach out to this number within 24 hrs